51st week of 2012 patent applcation highlights part 52 |
Patent application number | Title | Published |
20120322798 | Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2012-12-20 |
20120322799 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES - The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds. | 2012-12-20 |
20120322800 | Sepiapterin Reductase Inhibitors For The Treatment of Pain - Disclosed herein are small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and prodrugs and pharmaceutically acceptable salts thereof. The Also featured are pharmaceutical compositions of the compounds and uses of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, and neuropathic pain). | 2012-12-20 |
20120322801 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS - The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. | 2012-12-20 |
20120322802 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF - The present invention relates to novel 2,4-pyrimidine derivatives and a use thereof, and more particularly, to pyrimidine derivatives which are effective for systemic lupus erythematosus, a composition for preventing and treating systemic lupus erythematosus comprising the same as an active ingredient and a method for screening the same. The present inventors found novel materials inhibiting surface translocation of gp96 by mimicking a function of AIMP1 which is a molecular anchor for an intracellular residence of gp96, and identified in vitro and in vivo activity of the materials for preventing and treating SLE by alleviating SLE plasma in autoimmune diseases. Therefore, the present invention provides a novel method for screening a therapeutic agent for SLE, and preventing or treating SLE using the mechanism. | 2012-12-20 |
20120322803 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors - The present invention encompasses compounds of general formula (I) | 2012-12-20 |
20120322804 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS - Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. | 2012-12-20 |
20120322805 | PHARMACEUTICAL COMPOSITIONS OF SEMI-ORDERED DRUGS AND POLYMERS - A solid composition of a low-solubility drug and a concentration-enhancing polymer has a portion of the drug in a semi-ordered state. | 2012-12-20 |
20120322806 | QUINOXALINEDIONE DERIVATIVES - The present invention relates to compounds of formula (I) | 2012-12-20 |
20120322807 | STAT3/5 ACTIVATION INHIBITOR - The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: | 2012-12-20 |
20120322808 | Alpha 4 Beta 2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS - The present invention relates to novel α | 2012-12-20 |
20120322809 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS - The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. | 2012-12-20 |
20120322810 | NEW SALTS - The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament. | 2012-12-20 |
20120322811 | DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA - The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D | 2012-12-20 |
20120322812 | RUTAECARPINE DERIVATIVES FOR TREATING INSOMNIA - The teachings provided herein generally relate to compositions comprising a rutaecarpine derivative that activates CYP1A2 through enzyme induction. The uses for such a derivative, in some embodiments can include improving sleep, as well as treating insomnia. Other uses for the derivatives are provided herein. | 2012-12-20 |
20120322813 | RUTAECARPINE DERIVATIVES FOR TREATING CAFFEINE TOXICITY - The teachings provided herein generally relate to compositions comprising a rutaecarpine derivative that activates CYP1A2 through enzyme induction. The compound can be used for treating caffeine toxicity, in some embodiments. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein. | 2012-12-20 |
20120322814 | METHODS OF INHIBITING IRE1 - Disclosed herein are, inter alia, methods for inhibiting Ire1 activity. | 2012-12-20 |
20120322815 | PHARMACEUTICAL COMPOSITION CONTAINING A3 ADENOSINE RECEPTOR AGONIST - The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A | 2012-12-20 |
20120322816 | RUTAECARPINE DERIVATIVES FOR ACTIVATING CYP1A2 IN A SUBJECT - The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein. | 2012-12-20 |
20120322817 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof. | 2012-12-20 |
20120322818 | PHYCOTOXINS AND USES THEREOF - Pharmaceutical compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine and at least one additional compound are disclosed. Preparations for topical applications are provided that comprise an effective amount of the composition of the invention and a pharmacologically acceptable carrier. Methods of interfering with neuronal transmission comprising topical application of an effective amount of the at least one tricyclic 3,4-propinoperhydropurine are provided for treatment of a variety of indications that relate to muscle relaxation, anesthesia, muscle spasms and similar causes. | 2012-12-20 |
20120322819 | COMPOUND CONTAINING A NOVEL 4-ALKOXYPYRIMIDINE STRUCTURE AND MEDICINE CONTAINING SAME - Disclosed is novel compound and medicinal formulation containing same, possessing both angiotensin II receptor blocking and PPARγ activation effect, of use as a medicine for prevention and/or treatment of hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disturbances, post-ischemic peripheral circulatory damage, renal disease, arteriosclerosis, inflammatory disorder, type 2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinaemia. Further disclosed is the general formula I (where one or both of R | 2012-12-20 |
20120322820 | METHODS TO INHIBIT TUMOR CELL GROWTH BY USING PROTON PUMP INHIBITORS - Methods of treating one or more growth deregulated cells are disclosed. An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a growth deregulated cell outside of the gastric lumen of a subject. | 2012-12-20 |
20120322821 | GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA - The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease. | 2012-12-20 |
20120322822 | COMPOSITION CONTAINING CINCHONINE AS AN ACTIVE INGREDIENT FOR PREVENTING AND TREATING OBESITY, DYSLIPIDEMIA, FATTY LIVER, OR INSULIN RESISTANCE SYNDROME - The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases. | 2012-12-20 |
20120322823 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: | 2012-12-20 |
20120322824 | Cocaine Antagonist/Antidepressant Pharmaceutical Preparations - The present invention is a psychostimulant antagonist or antidepressant in pharmaceutical unit dosage form—with each unit dosage form containing in an effective amount to treat cocaine or amphetamine dependence in an animal or human in which such treatment is indicated and to whom one or more such unit dosage forms are administered—comprising one or more substituted or unsubstituted diphenyl piperidine derivative active agents according to Formula I: | 2012-12-20 |
20120322825 | AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS - An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided. | 2012-12-20 |
20120322826 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA - This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof with 5-HT4 agonistic activities, which is useful in the treatment of dementia. This invention also relates to a pharmaceutical composition for the treatment of dementia which comprises a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of dementia in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I) or a pharmaceutically acceptable salt thereof. | 2012-12-20 |
20120322827 | COMPOUNDS AND METHODS - Disclosed are compounds having the formula: | 2012-12-20 |
20120322828 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL - This invention provides methods of controlling pain in an equine for an effective period of time comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition. | 2012-12-20 |
20120322829 | USE OF A DIPYRIDYL COMPOUND FOR TREATING ROSACEA - A compound of formula (I) below: | 2012-12-20 |
20120322830 | Cyclourea Compounds as Calcium Channel Blockers - The invention relates to cyclourea compounds of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R | 2012-12-20 |
20120322831 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) - Novel small molecule compounds for reduction of Aβ 42 production and for treatment of Alzheimer's Disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described. | 2012-12-20 |
20120322832 | NICOTINIC ATTENUATION OF CNS INFLAMMATION AND AUTOIMMUNITY - The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof. | 2012-12-20 |
20120322833 | Pesticidal Arylpyrrolidines - The present invention relates to novel pesticidal arylpyrrolidine compounds (arylpyrrolidines) having the general formula (I) | 2012-12-20 |
20120322834 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: | 2012-12-20 |
20120322835 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME - A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1. | 2012-12-20 |
20120322836 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR STABILIZING THE SAME - Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis. | 2012-12-20 |
20120322837 | AMIDE COMPOUND AND MEDICINAL USE THEREOF - A compound of formula [I-W]: | 2012-12-20 |
20120322838 | Epothilone Compounds, Preparation Method and Use Thereof - Epothilone compounds represented by formula (I), their preparation methods and their use for preparing medicines are disclosed. The epothilone compounds are prepared by bioconversion and chemosynthesis or chemical modifications using epothilones or their derivatives as starting materials. Said epothilone compounds can be sued to treat proliferative diseases. | 2012-12-20 |
20120322839 | AQUEOUS DISPERSIONS - There is provided a method of making an aqueous dispersion wherein said dispersion comprises (A) one or more thickener and (B) solid particles of 1,2-benzisothiazolin-3-one, wherein said method comprises the steps of (a) forming an aqueous mixture (I) comprising water, a dissolved salt of 1,2-benzisothiazolin-3-one, and optionally one or more thickener, wherein the pH of said aqueous mixture (I) is 8.5 or higher, and (b) subsequently forming said aqueous dispersion by mixing together, in any order, components, wherein said components comprise an acid, said aqueous mixture (I), and optionally one or more thickener, wherein the pH of said dispersion is 1.5 to 7.5. Also provided is an aqueous dispersion made by that method. | 2012-12-20 |
20120322840 | Transdermally Absorbable Preparation Containing Basic Anti-Inflammatory Analgesic - A transdermally absorbable preparation in which a basic anti-inflammatory analgesic is formulated is provided to be an external adhesive patch, which has excellent drug releasing without damaging the physical properties of a plaster. The preparation can achieve high releasing of the basic anti-inflammatory analgesic without losing the releasing of the local anesthetic. Specifically provided is a transdermally absorbable adhesive patch, which contains both the basic anti-inflammatory analgesic and the local anesthetic as the absorption promoter for the basic anti-inflammatory analgesic. The basic anti-inflammatory analgesic has the acid dissociation constant (pKa) of 7 or more. The content of the basic anti-inflammatory analgesic is from 0.1% to 10% by weight to the total weight of the drug-containing plaster, and the content of the absorption promoter is from 0.01% to 20% by weight to the total weight of the drug-containing plaster in the transdermally absorbable adhesive patch. | 2012-12-20 |
20120322841 | Aldosterone Synthase Inhibitor - The present invention provides aldosterone synthase inhibitors of the formula: | 2012-12-20 |
20120322842 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to heterocyclyl-substituted alkylamino phenyl derivatives (I) to processes for the preparation thereof, to medicaments comprising them as well as to their use for the preparation of a medicament for the treatment of 5HT7 receptor mediated diseases or conditions. In the compounds (I) x-y-z together form —N—N═CR | 2012-12-20 |
20120322843 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLE - Provided herein are methods of administering 4-methylpyrazole (4-MP), or physiologically acceptable salts thereof, to subjects of genetic subpopulations expressing specific polymorphisms of the alcohol dehydrogenase and aldehyde dehydrogenase genes. Also provided herein are methods to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by consumption of ethanol, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects of these subpopulations. | 2012-12-20 |
20120322844 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. | 2012-12-20 |
20120322845 | POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE - The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof. | 2012-12-20 |
20120322846 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF SINGLE AND DOUBLE BLUNT-ENDED siRNA - The present invention provides methods of enhancing the efficacy and specificity of RNAi using single or double blunt-ended siRNA. The invention also provides single and double-blunt ended siRNA compositions, vectors, and transgenes containing the same for mediating silencing of a target gene. Therapeutic methods are also featured. | 2012-12-20 |
20120322847 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION - The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5′-terminal end 40 bases of the positive-sense RNA strand of the virus. | 2012-12-20 |
20120322848 | LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER - The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-( | 2012-12-20 |
20120322849 | Methods of Inhibiting Staphylobactin-mediated Iron Uptake in S. aureus - Methods of inhibiting | 2012-12-20 |
20120322850 | TRPM-2 ANTISENSE THERAPY - It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed. | 2012-12-20 |
20120322851 | ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES - The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer. | 2012-12-20 |
20120322852 | SMNdelta7 Degron: Novel Compositions and Methods of Use - The present invention includes an isolated nucleic acid comprising a nucleic acid sequence encoding a SMNΔ7 degron and the encoded polypeptide. The invention also includes inhibitors of SMNΔ7 degron. The invention also includes compositions and methods for mitigating SMN deficiency by targeting inhibition of factors that mediate SMNΔ7-degron dependent degradation of SMNΔ7. | 2012-12-20 |
20120322853 | TREATMENT OF PANCREATIC DEVELOPMENTAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A PANCREATIC DEVELOPMENTAL GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Pancreatic Developmental gene, in particular, by targeting natural antisense polynucleotides of a Pancreatic Developmental gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Pancreatic Developmental genes. | 2012-12-20 |
20120322854 | REGULATION OF MACROPHAGE ACTIVATION USING MIR-125B - The present disclosure relates to regulation of macrophage activation by delivering of miRNAs, for example miR-125 | 2012-12-20 |
20120322855 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference - Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism. | 2012-12-20 |
20120322856 | Method for Promoting Angiogenesis, Vascularization, or Vessel Repair or for the Inhibiting Tumor Angiogenesis - The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92. | 2012-12-20 |
20120322857 | METHODS OF INHIBITING TUMOR CELL AGGRESSIVENESS USING THE MICROENVIRONMENT OF HUMAN EMBRYONIC STEM CELLS - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 2012-12-20 |
20120322858 | Compositions and Methods for Inhibiting Expression of a Mutant Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene. | 2012-12-20 |
20120322859 | MicroRNA Fingerprints During Human Megakaryocytopoiesis - Described herein is a method of decreasing expression of HOXA1 in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject. | 2012-12-20 |
20120322860 | APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS - The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders. | 2012-12-20 |
20120322861 | Compositions and Methods for Treating Diseases - The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells. | 2012-12-20 |
20120322862 | Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders - The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to 4-1BB; pharmaceutical compositions comprising such 4-1BB aptamers; and methods of making and using the same. | 2012-12-20 |
20120322863 | PREVENTION OF AND COUNTERMEASURES AGAINST MITOCHONDRIAL DISEASE - The present invention relates to an agent containing L-arginine, 0.2 to 20 parts by weight of L-ascorbic acid per 1 part by weight of L-arginine, and, if desired, at least one selected from the group consisting of ribonucleic acids, ribonucleotides and ribonucleosides. The agent can treat mitochondrial disease which shows a variety of symptoms caused by dysfunction of mitochondria in cells. L-arginine contained in the agent for treating mitochondrial disease of the present invention increases an NO radical level to thereby dilate the arteries. L-ascorbic acid serves to mitigate a harsh taste and acrid feeling accompanied with the intake of L-arginine and eliminate excessive NO radicals. | 2012-12-20 |
20120322864 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF - Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type. | 2012-12-20 |
20120322865 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF - Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type. | 2012-12-20 |
20120322866 | COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL - A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ | 2012-12-20 |
20120322867 | Methods of Treating an Overweight or Obese Subject - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis. | 2012-12-20 |
20120322868 | FOOD PRODUCTS, PREPARATION, AND THERAPEUTIC METHODS - A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the Western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a Western diet. | 2012-12-20 |
20120322869 | ESTER COMPOUND AND USE THEREOF - An ester compound represented by formula (1):
| 2012-12-20 |
20120322870 | ESTER COMPOUND AND USE THEREOF - An ester compound represented by formula (1):
| 2012-12-20 |
20120322871 | POLYMERIC DELIVERY SYSTEM FOR A NONVISCOUS PROSTAGLANDIN-BASED SOLUTION WITHOUT PRESERVATIVES - This invention concerns an ophthalmic solution including:
| 2012-12-20 |
20120322872 | SUGAR ESTER PERACID ON SITE GENERATOR AND FORMULATOR - Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 2012-12-20 |
20120322873 | USE OF A BUFFER WITH A BIOCIDE PRECURSOR - Disclosed herein are biocidal compounds and compositions, methods of using said compounds and compositions, and systems and processes for their preparation. Particularly disclosed herein are in situ generated biocides stabilized with a buffer. The biocide may include in situ generated peracetic acid produced from a peroxygen source, an acyl group donor, and a buffer. | 2012-12-20 |
20120322874 | Pharmaceutical Uses - The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I | 2012-12-20 |
20120322875 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 2012-12-20 |
20120322876 | COSMETIC COMPOSITION COMPRISING A JASMONIC ACID COMPOUND - The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a jasmonic acid compound and a non-ionic associative polyurethane/polyether polymer. | 2012-12-20 |
20120322877 | (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS - The invention provides for novel (bis)urea and (bis)thiourea compounds which are inhibitors of lysine-specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer. | 2012-12-20 |
20120322878 | Polycationic Compounds And Uses Thereof - Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis. | 2012-12-20 |
20120322879 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS - The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof. | 2012-12-20 |
20120322880 | Pharmaceutical Formulations of Modafinil - Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants. | 2012-12-20 |
20120322881 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more guanidine fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of dodine, iminoctadine trialbesilate, iminoctadine triacetate, and guazatine | 2012-12-20 |
20120322882 | Compositions And Methods For Stimulating Hair Growth - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula (I) wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R | 2012-12-20 |
20120322883 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more benzamide fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of flutolanil, mepronil, and zoxamide | 2012-12-20 |
20120322884 | EPINEPHRINE NANOPARTICLES, METHODS OF FABRICATION THEREOF, AND METHODS FOR USE THEREOF FOR TREATMENT OF CONDITIONS RESPONSIVE TO EPINEPHRINE - The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions. | 2012-12-20 |
20120322885 | Materials and Methods for Improving Alcohol Metabolism and Alleviating the Effects of Hangovers - The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride. | 2012-12-20 |
20120322886 | USE OF A SATURATED AMINES COMPOUND IN MANUFACTURE OF MEDICAMENTS FOR MOBILIZING PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL - The invention provides a new use of a saturated amine compound, i.e., in manufacture of peripheral blood hematopoietic stem cell mobilizing agents. Experiments show that this compound (Code No. TA01) can efficiently mobilize hematopoietic stem cells into peripheral blood, and is a new type of hematopoietic stem cell mobilizing agents. The invention can play an important role in research and development of mobilizing agents for mobilizing hematopoietic stem cells into peripheral blood and has a promising application perspective. | 2012-12-20 |
20120322887 | NITISINONE FOR TREATMENT OF OCULOCUTANEOUS/OCULAR ALBINISM AND FOR INCREASING PIGMENTATION - A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (242-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC. | 2012-12-20 |
20120322888 | ANTIWRINKLE AGENT, LIPOLYSIS PROMOTER, EXTERNAL COMPOSITION FOR SKIN AND FOOD AND BEVERAGE COMPOSITION - An antiwrinkle agent, lipolysis promoter, external composition for skin, and food and beverage composition having for an active ingredient thereof a compound represented by general formula (1): | 2012-12-20 |
20120322889 | PLANT PROTECTION AGENT - The invention relates to the use of a compound according to formula (A) or formula (B), where R1, R4 and R5 are H, a glycoside, or an ester independently of each other, as a plant protection agent, wherein the plant protection agent comprises the compound, which is dissolved in a solvent at a concentration of 0.1 μM to 2 mM. | 2012-12-20 |
20120322890 | Inhibition of the Survival of Bone Cancer by Cyclohexenone Compounds from Antrodia Camphorata - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2012-12-20 |
20120322891 | RETINOID REPLACEMENTS AND OPSIN AGONISTS AND METHODS FOR THE USE THEREOF - Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided. | 2012-12-20 |
20120322892 | ORAL MICROEMULSION OF ELEMENE - An oral microemulsion of elemene is disclosed. The microemulsion is made of elemene, surfactant, cosurfactant and water or buffer solutions with pH 5˜8. Said surfactant is selected form tweens, polyoxyethylene castor oils, polyethylene glycol stearates and mixture thereof. Said cosurfactant is selected from ethanol, 1,3-propanediol, glycerol and mixture thereof. The concentration of elemene in the microemulsion is 1˜5 g/100 ml. The ratio of elemene, surfactant and cosurfactant is 1˜5(weight):1˜40(weight):1˜40(volume), wherein the unit of weight/volume is g/ml. | 2012-12-20 |
20120322893 | COARSE SUPPORT SILICA PARTICLES - The present invention relates to novel granular silicas for use as support material, especially as support for catalysts for fixed bed reactors, and to the production and use thereof. | 2012-12-20 |
20120322894 | Direct Compression Polymer Tablet Core - The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. | 2012-12-20 |
20120322895 | BIODEGRADABLE POLYMERIC NETWORKS AND METHODS FOR MANUFACTURING THE SAME - Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1. | 2012-12-20 |
20120322896 | NON-IONIC ASSOCIATIVE THICKENERS CONTAINING ALKYL CYCLOHEXYLOLS, FORMULATIONS CONTAINING THEM AND THEIR USES - New associative thickeners of the HEUR type (Hydrophobically modified Ethylene oxide URethane) whose hydrophobic monomer is based on alkyl cyclohexylols. These are new polyurethanes that allow a broad thickening of a medium shear gradient aqueous formulation while limiting the increase in the low shear gradient viscosity. The invention also concerns the compositions containing them and their uses in different formulations such as aqueous paints. | 2012-12-20 |
20120322897 | ESTOLIDE COMPOSITIONS EXHIBITING HIGH OXIDATIVE STABILITY - Provided herein are estolide compositions having high oxidative stability, said compositions comprising at least one compound of formula: | 2012-12-20 |